Subcutaneous Injection of Erythropoietin on Visual Functions in Patients With Late Onset Optic Neuropathy
NCT ID: NCT04469777
Last Updated: 2021-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
20 participants
INTERVENTIONAL
2019-04-01
2020-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Erythropoietin in Methanol Associated Optic Neuropathy: A Phase-2 Clinical Trial (EPO-MAON Study)
NCT02376881
Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial
NCT01962571
Treatment of Optic Neuropathies Using Autologous Bone Marrow-Derived Stem Cells
NCT02638714
Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa
NCT01560715
Effect of Intravitreal Bone Marrow Stem Cells on Ischemic Retinopathy
NCT01518842
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
All patients underwent initially assessment of visual acuity, color vision, pupil reaction ,funduscopy and electrophysiological tests ( pattern visual evoked potential and pattern electroretinogram in both eyes to use data of the normal fellow eye as patients' internal control). Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days). Follow up after one month and three months by recording visual acuity and electro physiological studies.
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Systemic erythropoietin injections
20 patients diagnosed as late onset optic neuropathy that were attending Alexandria main university hospital.Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
erythropoietin
Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
erythropoietin
Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alexandria University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohamed Fahmy Doheim
Prinicipal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mai ElBahwash, PhD
Role: PRINCIPAL_INVESTIGATOR
Alexandria Faculty of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alexandria Faculty of Medicine
Alexandria, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0304649
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.